Susrut Das1, Pradeep Kumar Gupta2, Rashmi Ranjan Das3. 1. Department of Pediatrics, Tata Main Hospital, Jamshedpur 831001, India rrdas05@gmail.com. 2. Department of Pediatrics, Tata Main Hospital, Jamshedpur 831001, India. 3. Department of Pediatrics, All India Institute of Medical Sciences, Bhubaneswar 751019, India.
Abstract
OBJECTIVE: To study the efficacy and safety of Saccharomyces boulardii (SB) in acute childhood rotavirus diarrhea. METHODS: Children (3 months to 5 years) with WHO-defined acute watery diarrhea and stool rotaviruspositive (n = 60) were randomized into intervention (n = 30) and control (n = 30) groups. The intervention group received SB (500 mg/day) for 5 days. RESULTS: The median duration (hours) of diarrhea was significantly shorter in the intervention group (60 vs. 89; 95% CI: -41.2 to - 16.8). A significantly shorter duration of hospitalization (74 vs. 91; 95% CI: -33.46 to - 0.54) was also seen in the intervention group, but no significant difference was seen for fever and vomiting. There was also no difference between the two groups in the proportion of children requiring parenteral rehydration and persistence of diarrhea lasting beyond day 7. There was no report of any adverse events. CONCLUSIONS: The present trial showed that SB is effective and safe in acute rotavirus diarrhea.
RCT Entities:
OBJECTIVE: To study the efficacy and safety of Saccharomyces boulardii (SB) in acute childhood rotavirus diarrhea. METHODS:Children (3 months to 5 years) with WHO-defined acute watery diarrhea and stool rotavirus positive (n = 60) were randomized into intervention (n = 30) and control (n = 30) groups. The intervention group received SB (500 mg/day) for 5 days. RESULTS: The median duration (hours) of diarrhea was significantly shorter in the intervention group (60 vs. 89; 95% CI: -41.2 to - 16.8). A significantly shorter duration of hospitalization (74 vs. 91; 95% CI: -33.46 to - 0.54) was also seen in the intervention group, but no significant difference was seen for fever and vomiting. There was also no difference between the two groups in the proportion of children requiring parenteral rehydration and persistence of diarrhea lasting beyond day 7. There was no report of any adverse events. CONCLUSIONS: The present trial showed that SB is effective and safe in acute rotavirus diarrhea.
Authors: Sue E Crawford; Sasirekha Ramani; Jacqueline E Tate; Umesh D Parashar; Lennart Svensson; Marie Hagbom; Manuel A Franco; Harry B Greenberg; Miguel O'Ryan; Gagandeep Kang; Ulrich Desselberger; Mary K Estes Journal: Nat Rev Dis Primers Date: 2017-11-09 Impact factor: 52.329
Authors: Shelui Collinson; Andrew Deans; April Padua-Zamora; Germana V Gregorio; Chao Li; Leonila F Dans; Stephen J Allen Journal: Cochrane Database Syst Rev Date: 2020-12-08